Molecular Therapy · 2017 · 244 citations · 24 references
MedicineBiotechnologyMolecular BiologyGene DeliveryGene TherapyOtologyCochlear DisordersEx Vivo Gene DeliveryEx Vivo Gene TherapyGene Delivery VectorsHearing ImpairmentHearing LossAdeno-associated Viral TransgenesisAuditory Hair Cell TransductionAuditory Hair CellsExosome-based TherapyHair Cell BiologyMammalian Hair Cells
Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. Gene therapy for hearing disorders is not as advanced, in part because gene delivery to sensory hair cells of the inner ear is inefficient. Although AAV transduces the inner hair cells of the mouse cochlea, outer hair cells remain refractory to transduction. Here, we demonstrate that a vector, exosome-associated AAV (exo-AAV), is a potent carrier of transgenes to all inner ear hair cells. Exo-AAV1-GFP is more efficient than conventional AAV1-GFP, both in mouse cochlear explants in vitro and with direct cochlear injection in vivo. Exo-AAV shows no toxicity in vivo, as assayed by tests of auditory and vestibular function. Finally, exo-AAV1 gene therapy partially rescues hearing in a mouse model of hereditary deafness (lipoma HMGIC fusion partner-like 5/tetraspan membrane protein of hair cell stereocilia [Lhfpl5/Tmhs−/−]). Exo-AAV is a powerful gene delivery system for hair cell research and may be useful for gene therapy for deafness. Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. Gene therapy for hearing disorders is not as advanced, in part because gene delivery to sensory hair cells of the inner ear is inefficient. Although AAV transduces the inner hair cells of the mouse cochlea, outer hair cells remain refractory to transduction. Here, we demonstrate that a vector, exosome-associated AAV (exo-AAV), is a potent carrier of transgenes to all inner ear hair cells. Exo-AAV1-GFP is more efficient than conventional AAV1-GFP, both in mouse cochlear explants in vitro and with direct cochlear injection in vivo. Exo-AAV shows no toxicity in vivo, as assayed by tests of auditory and vestibular function. Finally, exo-AAV1 gene therapy partially rescues hearing in a mouse model of hereditary deafness (lipoma HMGIC fusion partner-like 5/tetraspan membrane protein of hair cell stereocilia [Lhfpl5/Tmhs−/−]). Exo-AAV is a powerful gene delivery system for hair cell research and may be useful for gene therapy for deafness.
24
2016 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2016 · 5.1K citations
Medicine, Geriatric Medicine, Population Health Sciences +17
Joseph E. Rabinowitz, Fabienne Rolling, Chengwen Li et al. · Journal of Virology · 2002 · 750 citations · Full text